When a suboptimal clinical response is encountered with TNFIs or interleukins antagonists, what other strategies may be effective? How are these decisions made and where might an IL-6 inhibitor fit?

When a suboptimal clinical response is encountered with TNFIs or interleukins antagonists, what other strategies may be effective? How are these decisions made and where might an IL-6 inhibitor fit?

When a suboptimal clinical response has been encountered with TNFIs or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an IL-6 inhibitor fit?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Daniel Furst, MD

Daniel Furst, MD

Professor of Rheumatology
Carl M. Pearson Chair of Rheumatology
Director of Interventional Therapeutics
University of California, Los Angeles Medical Center for Health Sciences
Los Angeles, CA